Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

When Clinical Innovation Outpaces Implementation: A Dual Diffusion Model for GLP-1 Therapy and Employer Cardiometabolic Health.

Created on 19 Nov 2026

Authors

Steven L Halterman

Published in

Population health management. Pages 19427891261507912. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

Glucagon-like peptide-1 (GLP-1)-based and related incretin therapies have rapidly expanded from glycemic management to obesity and broader cardiovascular-kidney-metabolic care. Their population-health impact, however, depends on more than therapeutic efficacy. Translation into durable benefit requires clinicians to identify and manage appropriate patients, benefit systems to enable effective access, and patients to initiate and sustain treatment. This review applies diffusion of innovations theory to propose a dual diffusion model for GLP-1 therapy and employer cardiometabolic health. The model conceptualizes provider implementation and employer/plan effective access as interdependent organizational diffusion processes that converge on the patient treatment trajectory. Their interaction produces 4 implementation states: implementation failure, identification gap, access gap, and integrated opportunity. Employer/plan effective access is proposed as a construct extending beyond binary coverage to include eligibility, affordability, utilization management, provider access, administrative feasibility, continuity, and treatment-support infrastructure. The model further distinguishes treatment initiation from sustainability and introduces system-generated discontinuation as a conceptual description of treatment cessation driven by structural barriers. Clinically Integrated cardiometabolic optimization is proposed as an implementation architecture positioning pharmacotherapy within coordinated longitudinal management of cardiometabolic risk rather than as an isolated pharmacy intervention. Seven propositions define a research agenda for testing the model. As incretin therapies expand across cardiometabolic indications, closing the efficacy-to-implementation gap may become as consequential as further gains in pharmacologic efficacy.

PMID:
43053482
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement